425: Alumis to Merge with ACELYRIN, Creating Late-Stage Biopharma Focused on Immune-Mediated Diseases

Alumis and ACELYRIN have announced a merger agreement to create a well-capitalized, late-stage clinical biopharmaceutical company focused on developing and commercializing transformative therapies for immune-mediated diseases.

Summary

• Alumis and ACELYRIN have entered into a merger agreement, creating a combined entity focused on immune-mediated diseases.
• The merger will result in ACELYRIN stockholders receiving 0.4274 shares of Alumis common stock for each ACELYRIN share.
• Post-merger, Alumis stockholders will own approximately 55% and ACELYRIN stockholders approximately 45% of the combined company.
• The combined company will have approximately $737 million in pro forma cash as of December 31, 2024, extending the cash runway into 2027.
• The combined company will operate under the Alumis name and be led by the current Alumis executive team.
• The Alumis Board will expand to nine directors, including two additional directors from ACELYRIN's Board.
• The merger is expected to close in the second quarter of 2025, subject to stockholder approvals and customary closing conditions.
• The combined company's pipeline includes ESK-001 (TYK2 inhibitor) for psoriasis and SLE, A-005 (CNS-penetrant TYK2 inhibitor) for MS, and lonigutamab (anti-IGF-1R) for thyroid eye disease (TED).
• Topline data from the Phase 3 ONWARD trials for ESK-001 in psoriasis is expected in 1Q 2026.
• Topline data from the Phase 2b LUMUS trial in SLE is expected in 2026.
• A Phase 2 clinical trial for A-005 in MS is expected to be initiated in 2025, with topline data in 2026.
• Approximately $25-50 million of committed capital will be used to evaluate the potential of lonigutamab in TED.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the potential benefits of the combined company. However, it also acknowledges the risks and uncertainties associated with the transaction and clinical development.

Positives

• The merger creates a well-capitalized company with a diversified pipeline of late-stage clinical programs.
• The combined company has a strong cash position, providing runway into 2027.
• The pipeline includes multiple near-term catalysts, such as Phase 3 data for ESK-001 in psoriasis and Phase 2b data for ESK-001 in SLE.
• A-005 offers a first-in-class CNS-penetrant TYK2 inhibitor with potential in neuroinflammatory and neurodegenerative diseases.
• Lonigutamab provides an opportunity in thyroid eye disease with a potentially differentiated profile.
• The combined company will benefit from a world-class leadership team with a proven track record.

Negatives

• The merger is subject to stockholder approvals and customary closing conditions, which could delay or prevent the transaction.
• Integration of the two companies' operations and personnel could present challenges.
• Clinical trial outcomes are uncertain, and there is a risk that the pipeline assets may not achieve their expected potential.
• The company faces competition from other companies developing therapies for immune-mediated diseases.
• The company is subject to regulatory risks and the potential for delays in obtaining regulatory approvals.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals of the proposed transaction, including stockholder approvals, may not be received.
• The announcement, pendency, or completion of the proposed transaction may negatively impact the ability to attract, motivate, retain, and hire key personnel.
• The proposed transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the proposed transaction could arise.
• The company may be adversely affected by economic, business, and/or competitive factors.
• Restrictions during the pendency of the proposed transaction may impact the ability to pursue certain business opportunities or strategic transactions.
• The anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.
• Legislative, regulatory, economic, competitive, and technological changes could impact the company.
• The value of Alumis securities to be issued in the proposed transaction is subject to risk.
• Integration of the proposed transaction post-closing may not occur as anticipated.
• The effect of the announcement, pendency, or completion of the proposed transaction on the market price of the common stock of each of Alumis and ACELYRIN is uncertain.
• Challenges are inherent in developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new products and product candidates.
• The timing and costs involved in obtaining and maintaining regulatory approval for Alumis and ACELYRIN's current or future product candidates are uncertain.
• The market for, adoption, pricing, and reimbursement of Alumis and ACELYRIN's product candidates, if approved, are uncertain.
• Uncertainties exist in contractual relationships, including collaborations, partnerships, licensing, or other arrangements.
• The ability to establish and maintain intellectual property protection for products or avoid or defend claims of infringement is uncertain.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials exist.

Future Outlook

The combined company expects to advance its pipeline of clinical programs, including ESK-001, A-005, and lonigutamab, with multiple data readouts expected in the near term. The company anticipates a cash runway into 2027.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation and strategic partnerships to enhance pipeline development and commercialization capabilities, particularly in the competitive field of immune-mediated diseases. TYK2 inhibitors are an emerging class of drugs with significant market potential.

Comparison to Industry Standards

• ESK-001's Phase 2 OLE data shows PASI response rates in the high biologics range, suggesting it could compete with established treatments like Skyrizi, Cosentyx, and Stelara.
• A-005's CNS penetration could differentiate it from other TYK2 inhibitors and position it as a potential treatment for neuroinflammatory diseases like MS, where companies like Biogen, Novartis, and Roche are major players.
• Lonigutamab's potential as a best-in-class anti-IGF-1R therapy in TED could challenge Horizon Therapeutics' Tepezza, the current market leader.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger, with changes in ownership and potential value creation.
• Employees of both companies may experience changes in roles and responsibilities as a result of the integration.
• Patients with immune-mediated diseases could benefit from the development of new therapies by the combined company.
• Partners, suppliers, and other stakeholders of both companies may be affected by the merger.

Next Steps

• Obtain stockholder approvals from both Alumis and ACELYRIN.
• Satisfy other customary closing conditions.
• Close the merger transaction, expected in the second quarter of 2025.
• Finalize the clinical development plan for lonigutamab.
• Initiate Phase 2 study in MS patients for A-005 in 2H25.
• File a registration statement with the SEC.

Key Dates